Amphastar Pharmaceuticals, Inc. (AMPH) Total liabilities 2016–2025
Amphastar Pharmaceuticals, Inc. (AMPH) total liabilities at each fiscal year-end, per SEC filings.
$840.5MFY2025 · since FY2016: $98.5M → $840.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $840.5M | -0.6% |
| FY2024 | $845.2M | -3.2% |
| FY2023 | $873.5M | +309.5% |
| FY2022 | $213.3M | -5.6% |
| FY2021 | $226.0M | +23.8% |
| FY2020 | $182.5M | +14.5% |
| FY2019 | $159.4M | +6.9% |
| FY2018 | $149.2M | +27.2% |
| FY2017 | $117.3M | +19.1% |
| FY2016 | $98.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMPH financial trends
AMPH RevenueAMPH Net incomeAMPH Net marginAMPH Gross profitAMPH Gross marginAMPH Operating incomeAMPH Operating marginAMPH Operating cash flowAMPH Free cash flowAMPH Capital expendituresAMPH Return on equityAMPH Stock buybacksAMPH Dividends paidAMPH Total assetsAMPH Shareholders’ equityAMPH overview →